Physician profile
Farhad Farjoudi
NPI 1215251822
$6,051.92
in general payments reported to CMS, 2019-2025
43 companies · $1,265 in 2025
The $1,265 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $596 · 2021: $1,394 · 2022: $1,185 · 2023: $728 · 2024: $772 · 2025: $1,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,765.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,793.50 | 2020-2025 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $539.24 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $456.77 | 2019-2022 | |
| Amgen INC. | $419.70 | 2020-2025 | Evenity, Tepezza, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.99 | 2019-2024 | Jardiance, Tradjenta |
| Insulet Corporation | $255.94 | 2022-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $241.88 | 2020-2025 | |
| Mannkind Corporation | $181.99 | 2023-2025 | Afrezza |
| Abbvie INC. | $159.51 | 2020-2025 | |
| Abbott Laboratories | $154.41 | 2021-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $149.38 | 2021-2025 | Tymlos |
| Dexcom, INC. | $129.99 | 2020-2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $120.47 | 2021-2024 | Recorlev, Gvoke Hypopen |
| Antares Pharma, INC. | $106.76 | 2021-2025 | Xyosted |
| Medtronic, INC. | $106.04 | 2021-2024 | Minimed 780g |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhad Farjoudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.